PRKDC and neoplasm: At present, DNA‐PK inhibition is commonly used in tumor treatment in preclinical trials, while DNA‐PK inhibitors are usually only used as sensitizers of radiotherapy and chemotherapy but are ineffective when used alone in preclinical trials of tumor treatment.27, 28